STOCKHOLM, Jan. 7, 2024 /PRNewswire/ — Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that management will present at and participate in the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place January 8-11, 2024, in San Francisco, California. Calliditas will present an update on the company at 7:30 am PT… Continue reading Calliditas to present at JP Morgan Healthcare Conference
Tag: Morgan
IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2024 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 corporate guidance and program updates. 42nd Annual J.P. Morgan Healthcare ConferenceTuesday, January 9th, 2024… Continue reading IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
Strong revenue generation in Q4 2023, including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain Encouraging first results from first-in-human trial of HNSA-5487, Hansa’s lead candidate from the NiceR program for repeat dosing Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SRP-9001 in DMD … Continue reading Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
Strong revenue generation in Q4 2023, including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain Encouraging first results from first-in-human trial of HNSA-5487, Hansa’s lead candidate from the NiceR program for repeat dosing Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SRP-9001 in DMD … Continue reading Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
Cerapedics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WESTMINSTER, Colo., Jan. 5, 2024 /PRNewswire/ — Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, today announced that Valeska Schroeder, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference. The company presentation will take place on Monday, January 8, 2024, at 5:00 PM PST… Continue reading Cerapedics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
—ARIKAYCE® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales of Approximately $305.2 Million— —2024 Global ARIKAYCE Revenues Expected to be Between $340 Million and $360 Million, Reflecting Double-Digit Growth Compared to 2023— —Topline Data from the Phase 3 ASPEN Study of Brensocatib… Continue reading Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
MAA Announces Pricing of Senior Unsecured Notes Offering
GERMANTOWN, Tenn., Jan. 4, 2024 /PRNewswire/ — Mid-America Apartment Communities, Inc., (“MAA”) (NYSE: MAA) today announced that its operating partnership, Mid-America Apartments, L.P. (“MAALP”), priced a $350,000,000 offering of MAALP’s 5.000% senior unsecured notes due March 15, 2034 (the “Notes”) under its existing shelf registration statement. The Notes were priced at 99.019% of the principal amount. The… Continue reading MAA Announces Pricing of Senior Unsecured Notes Offering
Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 4, 2024 /PRNewswire/ — Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024. The company’s formal presentation… Continue reading Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 7:30… Continue reading Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Ceribell to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SUNNYVALE, Calif., Jan. 4, 2024 /PRNewswire/ — Ceribell, Inc.®, the developer of the first AI-powered point-of-care EEG system, announced today that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 8, 2024, at 8:00 a.m. Pacific Standard Time. Event:… Continue reading Ceribell to Present at the 42nd Annual J.P. Morgan Healthcare Conference